---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-093144"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2025-09-25T23:59:59+00:00"
generated_at: "2026-05-17T05:42:18.842512+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors

## Summary
- Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.
- Sanchez served as VP of Corp Comm & IR at Intra-Cellular Therapies, acquired by J&J for $14.6B in April 2025.
- He brings 30+ years experience in biotech, capital markets, and clinical medicine.
- Company plans to start Phase 1b program for NXP900, a precision oncology drug candidate.
- No arrangements or family relationships; no material transactions per Item 404(a).

## SEC filing metadata
- accession: 0001104659-25-093144
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2025-09-25T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465925093144/0001104659-25-093144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465925093144/tm2526892d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-093144
- JSON: https://secwatch.observer/filing/0001104659-25-093144.json
- Plain text: https://secwatch.observer/filing/0001104659-25-093144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.